Markets:

Overview

News

Currencies

International

Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

16.54 +16.54 (+972841.18%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Expert Ratings For NeuroPace ↗

April 06, 2022

Analysts have provided the following ratings for NeuroPace (NASDAQ:NPCE) within the last quarter:

Via Benzinga

Bear Of The Day: NeuroPace (NPCE) ↗

March 21, 2022

NeuroPace is a $200 million commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy.

Via Talk Markets

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

5 Analysts Have This to Say About NeuroPace ↗

May 13, 2022

Over the past 3 months, 5 analysts have published their opinion on NeuroPace (NASDAQ:NPCE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Recap: NeuroPace Q1 Earnings ↗

May 12, 2022

NeuroPace (NASDAQ:NPCE) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NeuroPace missed estimated earnings...

Via Benzinga

NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents

May 04, 2022

From NeuroPace, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

February 02, 2022

During Wednesday's session, 18 companies made new 52-week lows. Noteable 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) is the largest company in terms of market...

Via Benzinga

The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗

January 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 11, 2021

Gainers Liquidia (NASDAQ:LQDA) stock inc...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 07, 2022

On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (...

Via Benzinga

NeuroPace, Inc. (NPCE) Q3 2021 Earnings Call Transcript ↗

November 11, 2021

NPCE earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

58 Biggest Movers From Yesterday ↗

December 14, 2021

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-...

Via Benzinga

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts ↗

November 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...

Via Benzinga

50 Biggest Movers From Yesterday ↗

November 30, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...

Via Benzinga

Looking Into NeuroPace's Return On Capital Employed ↗

November 10, 2021

Benzinga Pro data, NeuroPace (NASDAQ:NPCE) reported Q2 sales of $12.63 million. Earnings fell to a loss of $4.61 million, resulting in a 18.87% decrease from last quarter. In Q1...

Via Benzinga

NeuroPace, Inc. (NPCE) Q2 2021 Earnings Call Transcript ↗

August 13, 2021

NPCE earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden

August 04, 2021

From NeuroPace

Via Business Wire

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

Could This Recently IPOed Medical Device Maker Make You Rich? ↗

July 03, 2021

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.

Via The Motley Fool

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗

September 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...

Via Benzinga

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs ↗

September 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

Earnings Scheduled For August 12, 2021 ↗

August 12, 2021

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.